Company Focus
IQVIA INC.
Latest IQVIA INC. News
Pharmaceutical
Rising use of innovative medicines and shifting spending patterns are reshaping the global pharmaceutical landscape, according to a new report from US data analytics group IQVIA. 27 June 2025
Related News
Insights
Company Spotlight
A Denmark-headquartered company that currently has a pipeline of three independent endocrinology rare disease product candidates in clinical development and is advancing oncology as its second therapeutic area of focus.
Latest News & Features of interest to IQVIA INC.
Biotechnology
The UK’s National Institute for Health and Care Excellence (NICE) has issued a positive recommendation for the use of AstraZeneca’s Imfinzi (durvalumab) in combination with Imjudo (tremelimumab) as a treatment option for adult patients with advanced or unresectable hepatocellular carcinoma (HCC). 30 July 2025
Biotechnology
Japanese drugmaker revealed that its in-house discovered tyrosine kinase inhibitor, Lenvima (lenvatinib mesylate), in combination with the anti-PD-1 antibody, pembrolizumab, and transarterial chemoembolization (TACE) has been approved by the National Medical Products Administration (NMPA) of China for unresectable, non-metastatic hepatocellular carcinoma. 30 July 2025
Pharmaceutical
Japanese drugmaker Takeda has announced earnings results for the first quarter of Japan’s fiscal year 2025, ending June 30. 30 July 2025
Biotechnology
US AI-focused start-up Formation Bio and IMIDomics, a precision medicine company focused on immune-mediated inflammatory diseases today announced that Formation Bio has licensed worldwide rights to IMIDomics' first-in-class anti-CD226 monoclonal antibody (MAb). 30 July 2025
Biotechnology
LTZ Therapeutics, a Sino-American biotech focused on immunotherapy, has announced a strategic research collaboration with US pharma major Eli Lilly. 30 July 2025
Pharmaceutical
Swiss pharma company Idorsia today released encouraging first half 2025 financial results, sending its shares up 8.5% to 2.94 francs in early trading. 30 July 2025
Pharmaceutical
Artbio, a US biotech specializing in radiopharmaceuticals, has raised $132 million in a series B financing to move its lead prostate cancer candidate AB001 through Phase II trials and build out a decentralized manufacturing network. 30 July 2025
Biotechnology
Apellis Pharmaceuticals has received clearance from the American medicines regulator for Empaveli (pegcetacoplan) as the first treatment to reduce proteinuria in patients aged 12 and older with C3 glomerulopathy (C3G) or primary immune complex membranoproliferative glomerulonephritis (IC-MPGN). 30 July 2025
Pharmaceutical
A new real-world analysis from UK drugmaker Indivior suggests that patients with opioid use disorder (OUD) treated with its once-monthly injectable buprenorphine formulation, BUP-XR, made significantly fewer emergency department visits than those who received no medication-assisted treatment. 29 July 2025
Pharmaceutical
A major US trial has found that structured healthy lifestyle programs can slow memory loss in older adults, regardless of their genetic risk for Alzheimer’s. The findings were released at the Alzheimer’s Association International Conference (AAIC). 29 July 2025
Latest In Brief for IQVIA INC.
Pharmaceutical
Ireland-based biopharma Jazz Pharmaceuticals has been called out for a couple of indiscretions by The Prescription Medicines Code of Practice Authority (PMCPA), which was established by the Association of the British Pharmaceutical Industry (ABPI) to operate the ABPI Code of Practice for the Pharmaceutical Industry. 11 July 2025
Latest Relevant Ones To Watch News
Last week, a US Food and Drug Administration (FDA) advisory committee (AdCom) voted against approval of Danish drugmaker Lundbeck and Japan-based Otsuka’s Rexulti for post-traumatic stress disorder. France’s Sanofi announced it is expanding its respiratory vaccines pipeline with an up to $1.6 billion acquisition of UK biotech Vicebio. French biotech Abivax released new Phase III data on its investigational ulcerative colitis candidate obefazimod that saw its shares nearly quadruple. Also of note was the latest setback for Sarepta’s Duchenne muscular dystrophy drug Elevidys, when the European Medicines human health committee, the CHMP, declined partner Roche’s accelerated approval of the drug. 27 July 2025
18 July 2025
Relevant Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze